Northwest Biotherapeutics plans to conduct public offering of stock

Aegis will assist; proceeds fund research and development activities

By Devika Patel

Knoxville, Tenn., June 29 - Northwest Biotherapeutics, Inc. will price a public offering of its common stock, according to a Form S-1 filed Friday with the Securities and Exchange Commission.

Aegis Capital Corp. is the underwriter.

Proceeds will be used for research and development activities, working capital and general corporate purposes.

Northwest is a development-stage biotechnology company based in Bothell, Wash.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.